Evidence map›Paper›PMID 42206040›Full record

ArticleFrontiers in immunology2026

Age-related and disease-specific changes in B-cell profiles in older adults with immune thrombocytopenia.

E Monzón Manzano, C Herrero Carrasco, P Acuña, L Del Pino Molina, E G Arias-Salgado, A Mendoza, R Kapur, L Porcelijn, M Martín Salces, M I Rivas Pollmar and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

E Monzón Manzano *Haematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
C Herrero Carrasco *Haematology and Haemotherapy Department, Severo Ochoa University Hospital, Madrid, Spain.
P AcuñaHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
L Del Pino MolinaClinical Immunology Department, La Paz University Hospital, and Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
E G Arias-SalgadoHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
A MendozaHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
R KapurSanquin Blood Supply Foundation, Research Department, and Amsterdam University Medical Center (UMC) location, Landsteiner Laboratory, Amsterdam, Netherlands.
L PorcelijnSanquin Diagnostic Services, Department of Immunohematology Diagnostics, Sanquin, Amsterdam, Netherlands.
M Martín SalcesHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
M I Rivas PollmarHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
E López-GranadosClinical Immunology Department, La Paz University Hospital, and Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Madrid, Spain.
V Jiménez YusteHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
M Gasior KabatHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
R Ramírez MartínFaculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
N ButtaHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.
M T Álvarez RománHaematology and Haemotherapy Department, La Paz University Hospital, Bleeding and Haemostasis Disorders Group-Health Research Institute of the La Paz University Hospital (IdiPAZ), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune thrombocytopenia is an autoimmune bleeding disorder that is more prevalent among older adults. Ageing itself reduces B-cell counts, a change also observed in patients with ITP. This study examined the B cell profiles of patients with ITP aged over 65 (ITP>65) and aged 65 or under (ITP ≤ 65). These ITP groups were compared with age-matched healthy controls to determine whether the observed differences were due to the disease itself or the effects of ageing. Methods: Blood samples were processed and stained using the EuroFlow 8-colour PIDOT and pre-germinal centre B-cell tubes, following the EuroFlow SOPs for staining cell surface membrane markers. Results: Patients with ITP>65, compared with those ≤65, showed reduced immature/transitional B cell subsets, an increased population of CD21-CD24- naïve B cells, and higher plasma B-cell activating factor levels. Comparison of the ITP ≤ 65 group with the HC ≤ 65 group showed that patients with ITP had a lower B-cell count, but a significant increase in the CD21-CD24- naïve B-cell subset. Patients with ITP>65 had expanded CD21-CD24- and CD21-CD24++ naïve and memory IgMD+ B-cell populations compared to Conclusion: These findings suggest that ageing induces modifications to the B-cell phenotype that are similar to those observed in patients with ITP, except for the expansion of the CD21-CD24- naïve B-cell subset,

Indexed as

AgingB-LymphocytesB-Lymphocyte SubsetsPurpura, Thrombocytopenic, IdiopathicAdultAgedAged, 80 and overAge FactorsB-Cell Activating FactorBiomarkersFemaleHumansImmunophenotypingLymphocyte CountMaleMiddle AgedB-Cell Activating FactorBiomarkersaged patientsBAFFB-cellsimmune thrombocytopaenianaïve B-cells

Identifiers

PMID42206040
PMCPMC13201400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.